Table 2. Pathological features and postoperative course.
| Case | Tumor size (cm) | pT | pN | p-Stage | Sarcomatous elements | Epitherial components | ly-factor | v-factor | Ddriver mutation | Adjuvant therapy | DFI (months) | Recurrent site | OS (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3.5 | 2a | 1 | II B | S | Sq | 1 | 1 | – | – | 54.6 | – | 54.6 | Dead |
| 2 | 5.4 | 3 | 0 | II B | S | Ad | 0 | 0 | – | – | 15.2 | BRA | 22.9 | Dead |
| 3 | 3.8 | 2a | 0 | I B | S | Sq | 0 | 1 | – | UFT-E | 41.6 | – | 41.6 | Dead |
| 4 | 10.0 | 4 | 1 | III A | S + P | Sq | 1 | 1 | – | – | 4.3 | – | 4.3 | Dead |
| 5 | 1.4 | 1b | 0 | IV A | –* | La | 0 | 0 | EGFR | CDDP + DOC | 92.8 | – | 92.8 | Alive |
| 6 | 2.9 | 3 | 2 | III B | S + P | Ad | 1 | 0 | – | – | 8.0 | PLE | 14.6 | Dead |
| 7 | 3.2 | 2a | 0 | I B | S | Ad | 0 | 0 | – | – | 5.6 | ADR | 10.1 | Dead |
| 8 | 4.2 | 2a | 2 | III A | S | Ad | 0 | 1 | – | – | 2.0 | PLE, OTH | 6.0 | Dead |
| 9 | 9.6 | 3 | 0 | II B | S + R | Ad > Sq | 1 | 1 | – | CDDP + DOC | 2.9 | LYM | 6.2 | Dead |
| 10 | 6.9 | 3 | 0 | II B | S + P | Sq | 1 | 1 | – | – | 40.1 | – | 60.9 | Alive |
| 11 | 3.9 | 2a | 0 | I B | S + G | – | 0 | 1 | – | UFT-E | 42.5 | – | 62.6 | Alive |
| 12 | 1.4 | 1b | 0 | I A2 | S + G | Ad | 0 | 0 | – | – | 30.8 | – | 30.8 | Dead |
| 13 | 3.2 | 2a | 0 | I B | S + P | AdSq | 0 | 1 | – | UFT-E | 3.5 | OSS, HEP | 4.6 | Dead |
| 14 | 9.8 | 4 | 0 | III A | S + G | Sq | 0 | 1 | – | – | 2.6 | HEP | 3.6 | Dead |
| 15 | 6.0 | 3 | 2 | III B | S | Ad | 1 | 1 | MET | CDDP + GEM | 4.5 | PUL | 32.9 | Alive |
| 16 | 9.0 | 4 | 1 | III A | S | Sq | 0 | 1 | – | CDDP + DOC | 21.0 | – | 30.6 | Alive |
| 17 | 10.0 | 4 | 0 | III A | S + G | – | 0 | 1 | – | – | 16.2 | – | 25.3 | Alive |
*Findings of lung lesions. This lesion is after spontaneous regression and chemotherapy. Spindle cells only in adrenal lesions. Ad: adenocarcinoma; ADR: adrenals; AdSq: adenosquamous carcinoma; BRA: brain; CDDP: cisplatin; DOC: docetaxel; DFI: disease-free interval; G: giant cell; GEM: gemcitabine; HEP: hepatic; La: large cell carcinoma; LYM: lymph nodes; OS: overall survival; OSS: osseous; P: pleomorphic cell; PLE: pleura; PUL: pulmonary; R: round cell; S: spindle cell; Sq: squamous cell carcinoma; UFT: tegafur/uracil.